Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2016

Open Access 01-12-2016 | Research

Mucopolysaccharidosis I; Parental beliefs about the impact of disease on the quality of life of their children

Authors: A. Soni-Jaiswal, J. Mercer, S. A. Jones, I. A. Bruce, P. Callery

Published in: Orphanet Journal of Rare Diseases | Issue 1/2016

Login to get access

Abstract

Background

Hematopoietic stem cell transplants, alongside enzyme replacement therapy and good multi-disciplinary care, have dramatically improved the life expectancy in children with Mucopolysaccharidosis (MPS) I, with better objective and functional outcomes. Despite these improvements, children with both the attenuated (non-Hurler) and severe (Hurler) variants of the disease have marked residual morbidity. Children with MPS I suffer with head and neck disease including obstructive sleep apnoea and hearing loss. The impact of these on quality of life has been poorly researched and no previous work has been published looking at patients’ perception of their own health, an important domain when considering the impact of treatment.

Methods

This exploratory qualitative study aimed to discover the effect of head and neck disease, alongside that of MPS I as a whole, on the quality of life of affected children.
A grounded theory approach was used to conduct this study. Children and their parents were invited to participate in semi-structured interviews. The transcribed interviews were coded and emergent themes explored until saturation occurred.

Results

The families of eleven children with MPS I were interviewed, five with Hurler’s and six with the attenuated non-Hurler’s. Important themes to emerge were- the fear of dying associated with obstructive sleep apnoea, difficulties communicating at school due to the delayed acquisition of language, chronic pain and restricted mobility, physical differences and restricted participation in social activities such as sports secondary to the musculoskeletal disease burden. The overall theme running through the analysis was the desire to fit in with ones peers.

Conclusion

Parents and children with MPS 1 worry about ‘fitting-in’ with broader society. The presence of airway disease has a profound impact on the emotional well being of parents whilst language delay and musculoskeletal disease have the biggest impact on the quality of life of the children themselves. It is important to understand the impact of MPS I on the quality of life of children and their families so that we may improve future treatment and management of this sub-group of children who have an increasing life span.
Literature
1.
Neufield EF, Muenzer J. The mucopolysachharidoses. In: Scriver CBA, Sly W, editors. The metabolic and molecular bases of inherited disease. New York: N: McGraw Hill; 2001. p. 3421–52.
2.
Meikle PJHJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.CrossRefPubMed
3.
Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008;3:24.CrossRefPubMedPubMedCentral
4.
Muenzer JWJ, Clarke LA. International Consensus Panel on, Management Treatment of Mucopolysaccharidosis, I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123(1):19–29.CrossRefPubMed
5.
Muenzer JB, Eng C, Giugliani R, Harmetz P, Martin R, Ramaswami U, Vellodi A, et al. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v4–12.CrossRef
6.
Scott HSBS, Gal A, Clark LA, Morris CP, Hopewood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical and biological implications. Hum Mutat. 1995;6(4):288–302.CrossRefPubMed
7.
Moreira GV, Kyosen SO, Patti CL, Martins AM, Tufik S. Prevalence of obstrucive sleep apnoea in patients with mucopolysaccharidosis type I, II and VI in a reference centre. Sleep Breath. 2014;18:791–7.CrossRefPubMed
8.
Lin H, Shih S, Chuang C, Lee K, Chen M, Lin H, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol Gen Metab. 2014;111:533–8.CrossRef
9.
Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al. Long-term outcome Hurler syndrome patients after hematopoitic cell transplantion: an internaitonl muticenter study. Blood. 2015;125(13):2164–72.CrossRefPubMed
10.
Wynn RF, Wraith JE, Mercer J, O'Meara A, Tylee K, Thornley M, Church HJ, Bigger BW. Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoitic Stem Cell Transplant Compare with Enzyme Replacement Therapy. J Pediatr. 2008;154:609–11.CrossRef
11.
Pulshiper MA. Long-term outcomes in MPS-IH: throwing stars. Blood. 2015;125(13):2016–7.CrossRef
12.
Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581–8.CrossRefPubMed
13.
de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme replacement therapy and/or hematopietic stem cell transplantion at diagnosis in patietns with mucopolysaccharidosis tyoe I; results of a European conensus procedure. Orphanet J Rare Dis. 2011;6:55.CrossRefPubMedPubMedCentral
14.
Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA. 1994;272:619–26.CrossRefPubMed
15.
Creswell JW. Qualitative Inquiry & Research Design. Choosing among five approaches. 2nd ed. Thousand Oaks, CA: Sage; 2007.
16.
Charmaz K. Constructing grounded theory. London: Sage; 2006.
17.
Papsin BC VA, Bailey CM, Raatcliffe PC, Leighton SEJ. Otologic and laryngologic manifestation of hte mucopolysaccharidosis after bone marrow transplanation. Otolaryngol Head Neck Surg. 1998;1998(1):30–6.CrossRef
18.
Yeung AHCM, Horn B, Rosbe KW. Airway Management in children with mucopolysaccharidosis. Arch Otolaryngol Head Neck Surg. 2009;135(1):73–9.CrossRefPubMed
19.
Nashed AA-SS, Gibbons J, MacLusky I, MacFarlane J, Riekstins A, Clarke J, Narang I. Sleep-related breathing in children with mucopolysaccharidosis. J Inherit Metab Dis. 2009;32(4):544–50.CrossRefPubMed
20.
Pal AR, Langereis EJ, Saif MA, Mercer J, Church HJ, Tylee KL, et al. Sleep disordered breathing in mucopolysaccharidosis I: a mulitvariant analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Orphanet J Rare Dis. 2015;10:42.CrossRefPubMedPubMedCentral
21.
Lin HYCM, Lin CC, Chen CP, Lin DS, Chuang CK, Niu DM, Chang JH, Lee HC, Lin SP. Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol. 2010;45(12):1205–12.CrossRefPubMed
22.
Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S. musculoskeletal manifestations of Hurler syndrome; long-term follow-up after bone marrow transplant. J Pediatr Orthop. 2004;2004(24):1.
23.
LA Clarke WJ, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229–40.CrossRefPubMed
24.
Rosen CPT, Larkin E, et al. Healt related quality of life and sleep disordered breathing in children. Sleep. 2002;25:657–63.PubMed
25.
Baldassari CMMR, Schubert C, Rudnick EF. Pediatric obstructive sleep apnea and quality of life: a meta-analysis. Otolaryngol Head Neck Surg. 2008;138(3):265–73.CrossRefPubMed
26.
Georgalas C, Tolley N, Kanagalingam J. Measuring quality of life in children with adenotonsillar disease with the child health questionnaire : a firtst UK study. Laryngoscope. 2004;114:1849–55.CrossRefPubMed
27.
Stewart MGD, Friedman E, et al. Quality of life and sleep study findings after adenotonsillectomy in children with bstructie sleep apnoea. Arch Otolaryngol Head Neck Surg. 2005;131:308–14.CrossRefPubMed
28.
Chervin RD, Dillon JE, Archbold KH. Conduct problems and symptoms of sleep disorders in children. J Am Acad Child Adolesc Psychiatry. 2003;42(2):201–8.CrossRefPubMed
29.
O'Brien L. The neurocognitive effects of sleep disruption in children and adolescents. Sleep Med Clin. 2011;6:109–16.CrossRef
30.
Gottleib DJ, Chase C, Vezina RM. Sleep-disordered breathing symptoms are associted with poorer cognitive funciton in 5-year old children. J Pediatr. 2004;145(4):458–64.CrossRef
31.
Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C. Mps Vi Study Group. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94(4):469–75.CrossRefPubMed
32.
Muenzer JB, Eng C, Giugliani R, Harmetz P, Martin R, Ramaswami U, Vellodi A, et al. Long-term open labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101.CrossRefPubMed
33.
Eiser C, Morse R. Can parents rate their child's health-related quality of life? Results of a systematic review. Qual Life Res. 2001;10(4):347–57.CrossRefPubMed
Metadata
Title
Mucopolysaccharidosis I; Parental beliefs about the impact of disease on the quality of life of their children
Authors
A. Soni-Jaiswal
J. Mercer
S. A. Jones
I. A. Bruce
P. Callery
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2016
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-016-0478-z

Other articles of this Issue 1/2016

Orphanet Journal of Rare Diseases 1/2016 Go to the issue

Research

Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net)

Research

Cytotoxic edema and diffusion restriction as an early pathoradiologic marker in canavan disease: case report and review of the literature

Research

Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China

Research

Hereditary angioedema due to C1 - inhibitor deficiency in Switzerland: clinical characteristics and therapeutic modalities within a cohort study

Research

Analysis of voice quality in patients with late-onset Pompe disease

Research

Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients